Psomagen Inc.

10/14/2025

Psomagen is proud to provide sequencing solutions for the Target ALS Foundation, a research consortium working to find treatments for Amyotrophic Lateral Sclerosis. In the global Natural History Study, long-read (conducted by Psomagen) and short-read sequencing have uncovered population genetic mutations, as well as indicators of disease progression over time.

Click the link for the full mention in the Pactals Congress 2025 Abstracts Book:

10/13/2025

In our most recent white paper, Psomagen’s lab compared the performance of the Illumina NovaSeq X Plus and the Ultima Genomics UG 100 when running 10x Genomics single-cell sequencing samples.

The goal of this paper was to evaluate data quality and consistency of 10x Chromium 3’ and 5’ technologies when run on different instruments. New technologies like Ultima wafers are critical to reducing the cost of large-scale single-cell sequencing projects.

For more details and data, read the full white paper at the link below: https://bit.ly/4nZohVh

10/09/2025

We're excited to begin offering Olink's new Target 48 Neurodegeneration panel in our labs! This new option for neuro researchers targets 41 key markers, detectable in low volume samples, with absolute quantification.

Get started with Olink in a trusted CSP lab today: https://hubs.ly/Q03KP-Tn0

10/08/2025

By combining transcriptomic, phenotypic, and Olink proteomic data, clinical researchers from UCSF have identified previously unknown candidate drug targets for the treatment of heart failure. This methodology expands on recent approaches to studying multi-organ aging.

If you want to get multiomics data too, Psomagen can help. Contact us to get started today.

Read the full study here: https://hubs.ly/Q03Ly9X40

10/06/2025

Our team is attending ASHG — and we'd love to meet with you to talk all things omics! Whether you need Sanger, NGS, third gen sequencing, proteomics, single-cell, or spatial biology, we've got cutting-edge instruments and expert staff.

Schedule time to chat at ASHG by clicking the links below.

Hobin Lim: https://bit.ly/4q9RM91
David Song: https://bit.ly/4q9RM91

10/01/2025

Last month, a Prince William County jury convicted Russell Marubbio in a landmark case. Somatic DNA evidence was used to secure a conviction for the first time in any US court. Psomagen conducted the microarray assays that provided the conclusive evidence that Russell, not his twin brother, was guilty of the 1987 crimes.

Read the full coverage from Potomac Local News: https://hubs.ly/Q03K5spX0

09/30/2025

We're excited to collaborate with Olink Proteomics to bring you this coffee break webinar! Hear from Dr. Jill Koshiol as she discusses how Olink PEA technology helped to identify circulating immune-related proteins associated with cancer risk in hepatitis B and hepatitis C cohorts.

Register here: https://bit.ly/4gzupBl

09/25/2025

Join us in welcoming our newest team member, Noura Darwish! Noura joins the Psomagen team after earning her PhD in Molecular and Cellular Biology at the University of Arizona. She's excited to bring her expertise in protein biochemistry to Psomagen customers as a sales representative for mid-US accounts.

Ready to start a conversation with Noura or one of our other salespeople? Visit our website to get started: https://hubs.ly/Q03FZF1Z0

09/24/2025

We're pleased to begin offering Xenium Protein subpanels to Psomagen customers! With spatial proteomics, detect transcripts and proteins on the same slide. Six subpanel options can target immune cells, tumor indicators, and more — visit our website for full details, and to start your project: https://hubs.ly/Q03KCMFF0

09/22/2025

Psomagen is honored to be one of eight WGS service providers for the NIH TOPMed program. This initiative is generating whole genome and other -omics data to improve our understanding of heart, lung, blood, and sleep disorders.

In this recent TOPMed-fueled paper, researchers analyzed whole genome data for LDL cholesterol. They identified hundreds of rare coding and non-coding gene associations, which will be used to better understand therapeutic targets for coronary artery disease. Psomagen was a partner providing WGS for this paper.

Read the full study here:

Background Rare genetic variation provided by whole genome sequence datasets has been relatively less explored for its contributions to human traits. Meta-analysis of sequencing data offers advantages by integrating larger sample sizes from diverse cohorts, thereby increasing the likelihood of disco...

09/18/2025

Today in spatial biology breakthroughs: researchers in the Netherlands have developed a method combining post-run fluorescent IHC with Xenium on post-mortem brain tissues that improves cell segmentation and transcript allocation. Read the paper here: https://go.nature.com/4n11dp3

If you want to try Xenium, Psomagen offers an end-to-end service from histology through data analysis — contact us today!

Investigating the suitability of different strategies for transcript allocation, including nuclear borders, expanded nuclear borders, and post-run immunostaining masks, for in situ sequencing data generated from postmortem human brains.

09/16/2025

New data just dropped! See what's included in an Olink Reveal report in the Psomagen lab. Reveal is a powerful option for discovery-level proteomics at an affordable price. WIth over 1,000 included proteins and 96% coverage of immune pathways, it could be the start of your next big breakthrough.

View the report here: https://hubs.ly/Q03FDYsr0